Jens Weidner’s Post

🌸A newly published paper by Irina Dijmărescu et al. #Quality of Life of #Pediatric Patients with #Chronic Intestinal, #Liver, and #Pancreatic Diseases During the #COVID-19 Pandemic Read more: https://lnkd.in/dk9yWdhw

A recent study from Indiana University School of Medicine reveals a significant correlation between primary ciliary dyskinesia (PCD) and asthma in children. The research, published in JAMA Network Open, indicates that children with PCD are 22 times more likely to have asthma compared to those without the disorder. This finding underscores the necessity for routine asthma screening in children with PCD and suggests that some asthma cases may involve undiagnosed PCD. The study analyzed 266 pediatric records, highlighting the importance of recognizing overlapping symptoms for improved respiratory outcomes in young patients.

Urgent Insights on Pediatric COVID-19 Complications: Acute Kidney Injury Led by Rupesh Raina , MD, FAAP,FACP,FASN and FNKF, Isabelle Mawby, Ronith Chakraborty, Sidharth Kumar Sethi, Kashin Mathur, Shefali Mahesh MD, MBA, Michael Forbes of distinguished researchers, this study found that out of 2,546 pediatric patients with COVID-19, 10.8% developed AKI. These patients faced not only longer hospital stays but also higher mortality risks compared to their peers without AKI. 🔎 Key findings include: Increased need for airway, cardio-respiratory, and kidney support in AKI patients. Substantial risk enhancements visible in Pediatric Index of Mortality (PIM) scores. These insights are crucial as they underscore the need for heightened vigilance and tailored care strategies to mitigate long-term health impacts on our youngest population. 📖 Full study and preventive measures: https://lnkd.in/dVhPMbxq 🎓 Earn 1.0 CME credit by engaging with our detailed analysis. #PediatricCare #COVID19 #KidneyHealth #MedicalResearch #PhysicianInsights #cme

📃Scientific paper: Health-related quality of life of children with X-linked hypophosphatemia in Germany Abstract: Background X-linked hypophosphatemia (XLH) is a rare inherited phosphate-wasting disorder associated with bone and dental complications. Health-related quality of life (HRQoL) is reduced in XLH patients on conventional treatment with phosphate supplements and active vitamin D, while information on patients treated with burosumab is rare. Methods HRQoL was assessed in 63 pediatric XLH patients participating in a prospective, observational study and patient registry in Germany using the KIDSCREEN-52 survey instrument and standardized qualitative interviews. Results The median age of the XLH patients was 13.2 years (interquartile range 10.6 – 14.6). At the time of the survey, 55 (87%) patients received burosumab and 8 (13%) conventional treatment. Forty-six patients (84%) currently being treated with burosumab previously received conventional treatment. Overall, HRQoL was average compared to German reference values (mean ± SD: self-report, 53.36 ± 6.47; caregivers’ proxy, 51.33 ± 7.15) and even slightly above average in some dimensions, including physical, mental, and social well-being. In general, XLH patients rated their own HRQoL higher than their caregivers. In qualitative interviews, patients and caregivers reported that, compared with conventional therapy, treatment with burosumab reduced stress, bone pain, and fatigue, improved physical health, and increased social acceptance by peers and the school environment. Conclusions In this real-world study in pediatric... Continued on ES/IODE ➡️ https://etcse.fr/Yl7xc ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

Children and teens with inflammatory bowel disease (IBD) face unique challenges, from severe disease progression to limited treatment options. 📈 As the incidence of paediatric IBD rises, early diagnosis and effective, personalized treatments are crucial. Explore the latest insights on disease management, promising therapies, and the critical need to close knowledge gaps between paediatric and adult care in this recent article published by journal of Chron’s and Colitis. 🔗 https://lnkd.in/dJQManWB #Paediatrics #PaediatricCare #PedsICU #Neonatology #ChildHealth

A recent study published in JAAOS: Global Research and Reviews reveals a concerning trend of increasing Scurvy incidence in pediatric patients in the US. The disease, caused by vitamin C deficiency, more than tripled from 2016 to 2020, affecting younger males from low-income households. Patients often have concomitant diagnoses like autism spectrum disorder and obesity. The study emphasizes the importance of considering Scurvy in differential diagnoses to prevent delayed treatment and associated burdens.

Before I switch next week to focus on pharmacy spending in 2023, let's continue to look at the overall utilization trends by therapy areas per the IQVIA Use of Medicine in the US 2024 report. 📈 No surprise, obesity growth was the largest at 45.1% 📈 Other areas of growth include immunology, genitourinary, lipid therapy, and gastrointestinal 📈 Diabetes and cardiovascular disease both just missed out of the top 5 at 9.3% growth Contraception has the biggest decrease, we will dive into that later this week! Interesting detail about the increase in GI days of therapy- this was driven by an increase in colonoscopies in 2023 creating a higher demand for bowel prep. This is a much-needed growth area after the decline in preventative health items associated with the pandemic!

Each month, the OMA Pediatric Committee reviews key obesity-focused research to keep you informed on the latest developments. September’s update explores maternal and perinatal risk factors for pediatric nonalcoholic fatty liver disease. Dive into the full review at https://bit.ly/3TJqIif. #PediatricObesity #ObesityResearch #MaternalHealth #PerinatalHealth #ObesityMedicine

🌟 Research Announcement in Pediatric Healthcare 🌟 I am happy to announce that our latest article, “Investigating Procalcitonin and C-Reactive Protein as Diagnostic Biomarkers in Pediatric Suspected Meningitis: A Forward-Looking Observational Analysis,” has been accepted for publication in the International Journal of Innovative Science and Research Technology. This study, delves deep into the predictive values of CRP and PCT in diagnosing meningitis among children. Despite the widespread use of these biomarkers, our findings challenge the status quo, revealing that PCT does not play a significant role in predicting meningitis, while CRP, albeit with limitations, shows a positive correlation in its prediction. The implications of our research are profound, emphasizing that a comprehensive CSF analysis remains the gold standard in diagnosing meningitis, over any singular biomarker. This work not only adds to the existing body of knowledge but also guides clinicians towards more accurate and reliable diagnostic practices. I am immensely grateful to my co-researchers, our supportive institutions, and, most importantly, the families who participated in this study. This achievement reflects our collective commitment to enhancing pediatric care and outcomes. Publication link is https://lnkd.in/gfCCYCB7 Let’s continue to push the boundaries of pediatric healthcare together! #Pediatrics #MeningitisResearch #DiagnosticBiomarkers #MedicalInnovation #ResearchImpact

⚠️ Pediatric rare disease research faces immense challenges—95% of rare diseases have no approved treatments, and the average time to diagnosis is 4.8 years. This delay results in 30% of children with rare diseases dying before their 5th birthday. We must change this reality. DATAcc by DiMe’s new project is addressing the barriers that #pediatric clinical trials face such as costs, risk, and the lack of tools needed to make this process more efficient and equitable. In developing core digital measures for pediatric rare disease, we will collectively create the resources necessary to: ▪️ Drastically reduce costs ▪️ Streamline clinical trials and reduce risk ▪️ Accelerate the delivery of treatments to the children who need them most Join DATAcc by DiMe in this collaborative, multi-stakeholder effort to create a set of core digital measures for pediatric rare disease that will accelerate lifesaving therapies for the 200 million children worldwide. 🙏 No family or caregiver with a child facing a rare disease should be left waiting years for a diagnosis and even longer for treatment—join us: https://lnkd.in/etepngmc